Do you want to read an article? Please log in or register.
Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Genitourinary Cancer
Related content
COMMENTED
Genitourinary Cancer
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
BJU Int
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M, EuroGemDoce Study Group Collaborators, European Association of Urology ‐ Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group
doi: 10.1111/bju.16645
Genitourinary Cancer
A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer
Eur Urol
Ghodoussipour S, Bivalacqua T, Bryan RT, Li R, Mir MC, Palou J, Psutka SP, Sundi D, Tyson MD, Inman BA
doi: 10.1016/j.eururo.2025.02.010
Genitourinary Cancer
Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort
J Urol
Lotan Y, Krishna V, Abuzeid WM, Launer B, Chang SS, Krishna V, Shingi S, Gordetsky JB, Gerald T, Woldu S, Shkolyar E, Hayne D, Redfern A, Spalding L, Stewart C, Eyzaguirre E, Imtiaz S, Narayan VM, Packiam VT, O'Donnell MA, Li R, Baekelandt L, Joniau S, Zuiverloon T, Fernandez MI, Schultz M, Hensley PJ, Allison D, Taylor JA, Hamza A, Kamat A, Nimgaonkar V, Sonawane S, Miller DL, Watson D, Vrabac D, Joshi A, Shah JB, Williams SB
doi: 10.1097/JU.0000000000004278
Genitourinary Cancer
Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial
BJU Int
Conroy S, Jubber I, Noon AP, Rosario DJ, Griffin J, Morgan S, Hubbard R, Kennish S, Mitchell S, Venugopal S, Linton K, Rajasundaram R, Hussain SA, Catto JWF
doi: 10.1111/bju.16516
Genitourinary Cancer
Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy
BJU Int
Subiela JD, de la Parra I, Taborda J, Medina AA, Pichler R, Krajewski W, Ojeda CM, Mardomingo AF, Durán PDO, Pérez EL, González-Padilla DA, Aumatell J, Mori K, Scilipoti P, Longoni M, de Angelis M, Caño-Velasco J, Puentedura AL, Pujol LP, Contieri R, Gallioli A, Tukiendorf A, D'Andrea D, Teoh JY, Afferi L, Del Giudice F, Marcq G, Albisinni S, Soria F, Mertens LS, Laukhtina E, Tully K, Mari A, Guerrero-Ramos F, Alvarez-Maestro M, Martín CC, Melendres FA, Buisan O, López-González JA, Dominguez-Escrig JL, Aranda J, Elena JLR, Basile G, Santos VGD, Moschini M, Pradere B, Acosta EA, Palacio FL, Puig AC, Gajate P, Saiz A, Gontero P, Revilla FJB, From Young Academic Urologist: Urothelial Carcinoma Working Group
doi: 10.1111/bju.16913
Genitourinary Cancer
The impact of treatment for muscle-invasive bladder cancer on health-related quality of life
BJU Int
Nuijens ST, van Hoogstraten LMC, Terpstra NB, Beeren I, Vrieling A, Wijnen EM, Meijer RP, Kiemeney LA, Witjes JA, Aben KKH
doi: 10.1111/bju.16736
Lung, Respiratory and Thoracic Cancer
Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy
J Thorac Oncol
Wiesweg M, Alaffas A, Rasokat A, Saalfeld FC, Rost M, Assmann C, Herster F, Hilbrandt M, Griesinger F, Kron A, Roeper J, Glanemann F, Kropf-Sanchen C, Reck M, Kulhavy J, Stenzinger A, Wolf J, Sebastian M, Schuler M, Wermke M, Frost N, Kopp HG, Christopoulos P, Scheffler M
doi: 10.1016/j.jtho.2025.04.016
SPECIAL REPORT
Breast Cancer
Managing Side Effects in Breast Cancer Treatment
SPECIAL REPORT
Breast Cancer